FDAAA Cornucopia: REMS To Be Used Sparingly; Trial Database On Schedule
Executive Summary
FDA will use its authority to require risk evaluation and mitigation strategies judiciously, according to Chief Medical Officer and CDER Acting Director Janet Woodcock